multiplex-immunofluorescence-combined-with-spatial-image-analysis-for

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

The tumor microenvironment (TME) is composed of a plethora of different cell types, such as cytotoxic immune cells and immunomodulatory cells. Depending ...

Université Catholique de Louvain (UCLouvain)

The aim of this study was to assess the validity of a treatment strategy for T1N0 glottic squamous cell carcinoma.

Prospective validation of an institutional treatment strategy for T1N0M0 glottic carcinoma.

In 2019, the FDA approved pembrolizumab, a monoclonal antibody targeting PD-1, for the first-line treatment of recurrent or metastatic head and neck cancers, despite only a limited number of patients benefiting from the treatment. Promising effects of therapeutic vaccination led the FDA to approve the use of the first therapeutic vaccine in prostate cancer in 2010. Research in the field of therapeutic vaccination, including possible synergistic effects with anti-PD(L)1 treatments, is evolving each year, and many vaccines are in pre-clinical and clinical studies. The aim of this review article is to discuss vaccines as a new therapeutic strategy, particularly in the field of head and neck cancers. Different vaccination technologies are discussed, as well as the results of the first clinical trials in HPV-positive, HPV-negative, and EBV-induced head and neck cancers.

Article	Year
Prospective validation of an institutional treatment strategy for T1N0M0 glottic carcinoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology\| PubMed ID: 30940421	2019
Vaccine-Based Immunotherapy for Head and Neck Cancers. Cancers\| PubMed ID: 34885150	2021

Simon Beyaert

Biography

JoVE Journal Publications

Other Publications